Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Deffered Revenue (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 10.6% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 10.6% year-over-year, with the annual reading at $4.9 million for FY2025, 10.6% down from the prior year.
  • Non-Current Deffered Revenue hit $4.9 million in Q4 2025 for Immunocore Holdings, down from $5.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $8.6 million in Q4 2021 to a low of $4.9 million in Q4 2025.
  • Historically, Non-Current Deffered Revenue has averaged $5.6 million across 5 years, with a median of $5.5 million in 2024.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 73.69% in 2021 and later rose 8.56% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $8.6 million in 2021, then tumbled by 41.19% to $5.1 million in 2022, then rose by 8.56% to $5.5 million in 2023, then decreased by 1.47% to $5.4 million in 2024, then decreased by 10.6% to $4.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for IMCR at $4.9 million in Q4 2025, $5.0 million in Q3 2025, and $5.2 million in Q2 2025.